Sale!

ATN1 Gene Dentatorubral-Pallidoluysian Atrophy Genetic Test Cost

Name: ATN1 Gene Dentatorubral-Pallidoluysian Atrophy Genetic Test Cost
SKU: TEST-1240
Price: 4400 AED
Availability: InStock

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The ATN1 Gene Dentatorubral-Pallidoluysian Atrophy (DRPLA) Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at detecting mutations in the ATN1 gene, which are responsible for causing Dentatorubral-Pallidoluysian Atrophy. DRPLA is a rare, autosomal dominant neurodegenerative disorder characterized by a wide range of neurological symptoms, including ataxia, choreoathetosis, seizures, and cognitive decline, which tend to worsen over time. The onset of symptoms can vary greatly, appearing in childhood or adulthood, making early and accurate diagnosis crucial for managing the condition.

This genetic test involves analyzing the patient’s DNA to identify mutations in the ATN1 gene that indicate the presence of DRPLA. By pinpointing these genetic abnormalities, healthcare providers can confirm a diagnosis of DRPLA, allowing for early intervention, appropriate management strategies, and genetic counseling for affected families. The test cost is set at 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the specific genetic alterations associated with this condition.

Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and commitment to providing accurate, reliable results, the ATN1 Gene DRPLA Genetic Test represents a crucial resource for individuals and families at risk of this challenging disorder, offering hope for better understanding and management of their condition.

Description

ATN1 Gene Dentatorubral-pallidoluysian atrophy Genetic Test

Components: ATN1 Gene Dentatorubral-pallidoluysian atrophy Genetic Test

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for ATN1 Gene Dentatorubral-pallidoluysian atrophy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ATN1 Gene Dentatorubral-pallidoluysian atrophy.

Test Details: Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare genetic disorder that affects the brain and nervous system. It is caused by mutations in the ATN1 gene, which provides instructions for making a protein called atrophin-1. The mutation leads to an abnormal form of the protein that accumulates in the brain, causing damage to the neurons. NGS (next-generation sequencing) genetic testing can be used to identify mutations in the ATN1 gene. This test involves sequencing the entire gene to detect any changes or abnormalities that may be present. NGS testing is a powerful tool that can detect even small changes in the DNA sequence, making it an effective method for diagnosing genetic disorders like DRPLA. If a mutation is detected in the ATN1 gene, it can confirm a diagnosis of DRPLA and help guide treatment and management options. While there is currently no cure for DRPLA, early diagnosis and management can help improve quality of life for affected individuals and their families.

Test Name	ATN1 Gene Dentatorubral-pallidoluysian atrophy Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for ATN1 Gene Dentatorubral-pallidoluysian atrophy NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ATN1 Gene Dentatorubral-pallidoluysian atrophy
Test Details	Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare genetic disorder that affects the brain and nervous system. It is caused by mutations in the ATN1 gene, which provides instructions for making a protein called atrophin-1. The mutation leads to an abnormal form of the protein that accumulates in the brain, causing damage to the neurons. NGS (next-generation sequencing) genetic testing can be used to identify mutations in the ATN1 gene. This test involves sequencing the entire gene to detect any changes or abnormalities that may be present. NGS testing is a powerful tool that can detect even small changes in the DNA sequence, making it an effective method for diagnosing genetic disorders like DRPLA. If a mutation is detected in the ATN1 gene, it can confirm a diagnosis of DRPLA and help guide treatment and management options. While there is currently no cure for DRPLA, early diagnosis and management can help improve quality of life for affected individuals and their families.